Computational pathology to predict docetaxel benefit in patients with metastatic hormone-sensitive prostate cancer from the CHAARTED trial (ECOG-ACRIN E3805). This is an ASCO Meeting Abstract from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback